％0刊期刊文章％aekström，magnus％ajhrance，Miriam J.％A Huang，Chao％A Currow，David C.％T平均临床上的重要差异，最佳，最糟糕，目前的强度和慢性呼吸困难的不愉快和令人不快的差异。％D2020％R 10.19.1183 / 13993003.02202-2019％J欧洲呼吸期杂志％p 1902202％v 56％n 2％x背景慢性呼吸困难对后果造成破坏性后果。电流强度的最小临床重要差异（MCID）估计为100 mm的视觉模拟量表（VAS）上为9毫米。我们旨在确定常用尺寸和召回时期的McID：过去24小时的目前令人不愉快和当前，平均，最糟糕的强度，用于慢性呼吸困难。方法这是对吗啡对吗啡的随机对照试验的二次分析患有严重疾病的慢性呼吸困难的人7天。每天晚上在100毫米VAS上使用日记，自我报告的呼吸困难分数。使用基于锚和分布的方法估计每个分数的MCID。结果283名参与者（平均年龄74.2岁; 63％的男性; 58％COPD; 87.0％修改的医学研究委员会（MMRC）得分3-4）包括在内。基于锚的MCID用于呼吸困难分数范围为-13.9 mm至-9.5 mm。在使用不同的锚点和所有参与者时，MCID也相似，以及更严重的呼吸困难（MMRC 3-4）的参与者。 Distribution-based effect sizes were classed as small (−4.7−6.3 mm), moderate (−9.4−12.5 mm) and large (−15.0−20.0 mm) effect. Sample sizes for trials using the different scores were proposed. MCIDs of absolute change were more stable than using relative change from baseline.Conclusion An improvement of ∼10 mm on a 100-mm VAS is likely to be clinically meaningful across commonly used measures of chronic breathlessness (current intensity, unpleasantness, and average, best and worst intensity over the past 24 h) to evaluate clinical benefit and effects in therapeutic trials.This cohort study determined clinically important differences for current intensity and unpleasantness and the average, best and worst intensity of the past 24 h of chronic breathlessness, which is important for the design of therapeutic trials https://bit.ly/3amslss %U //www.qdcxjkg.com/content/erj/56/2/1902202.full.pdf